Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Arbaclofen Placarbil · XP-19986

Small molecule

Phase 2 Most advanced trial (none active)
3 Registered trials

What is Arbaclofen Placarbil?

Arbaclofen placarbil is an oral prodrug formulation tested in immediate-release, sustained-release and modified-release tablet and capsule forms. It is studied in gastroesophageal reflux disease, alcohol use disorder and healthy volunteers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XP-19986, Eudragit RL 100
Drug type
Small molecule
Therapy area
Gastroenterology, Psychiatry
In trials of
INDV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
W89H91R7VX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02511886 Phase 2 Alcohol Use Disorder Completed INDV
NCT00838396 Phase 2 GERD Completed INDV
NCT03058237 Phase 1 Healthy Volunteers Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alcohol Use DisorderGERDHealthy Volunteers

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.